Diurnal
ExitedDiurnal is an innovative UK-based specialty pharmaceutical company dedicated to developing hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions
Diurnal is tracked in the Tech.eu funding database. Based in Cardiff, UK; active in Healthtech. Acquired by Neurocrine in 2022. Data as of Nov 2026.
Cardiff, UKwww.diurnal.com ↗
Total raised
—
no tracked rounds
Funding rounds
0
Investors
0
distinct backers
Active since
—
Funding rounds
0 roundsNo funding rounds recorded.
Exit
Type
acquisition
Date
Aug 2022
Value
€56M
Acquiror
Neurocrine (United States of America)
Related news
- Cardiff MedTech set for £48m takeoverbusinesscloud.co.uk · 2022-08
Similar companies
same sector, similar size- Clinithink—UK · Healthtech
- Chiron Health AI—UK · Healthtech
- Ascentys—UK · Healthtech
- Stent Tek—UK · Healthtech
- MYndspan—UK · Healthtech
- Neoss—UK · Healthtech
Global coverage: FundingData